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Abstract 
The sirtuin/nicotinamide adenine dinucleotide (NAD) system is implicated in development of type 2 
diabetes (T2D) and diet-induced obesity, a major risk factor for T2D. Mechanistic links have not yet 
been defined. Sirtuin/NAD system gene expression and NAD/NADH levels were measured in liver, 
white adipose tissue (WAT) and skeletal muscle from mice fed either a low-fat diet (LFD) or high-fat 
diet (HFD) for 3 days up to 16 weeks. An in-house custom designed multiplex gene expression assay, 
assessed all 7 mouse sirtuins (SIRT1-7) and 16 enzymes involved in conversion of tryptophan, niacin, 
nicotinamide riboside and metabolic precursors to NAD. Significantly altered transcription was 
correlated with body weight, fat mass, plasma lipids and hormones. Regulation of the sirtuin/NAD 
system was associated with early (SIRT4, SIRT7, NAPRT1, NMNAT2) and late phases (NMNAT3, 
NMRK2, ABCA1, CD38) of glucose intolerance. TDO2 and NNMT were identified as markers of HFD 
consumption. Altered regulation of the SIRT/NAD system in response to HFD was prominent in liver 
compared to WAT or muscle. Multiple components of the sirtuins and NAD biosynthetic enzymes 
network respond to consumption of dietary fat.  Novel molecular targets identified above could 
direct strategies for dietary/therapeutic interventions to limit metabolic dysfunction and 
development of T2D. 
 
Key words glucose intolerance; high-fat diet; nicotinamide adenine dinucleotide; mouse; sirtuin 
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1. Introduction 
An impaired sirtuin/nicotinamide adenine dinucleotide (NAD) system is linked to development of 
type 2 diabetes (T2D) [1-3]. Obesity and associated abnormal glucose and lipid metabolism, major 
risk factors for development of T2D, are also associated with reduced activity of the sirtuin/NAD 
system [1-3]. The specific components of the sirtuin/NAD system involved in diet-induced obesity 
and the development of glucose intolerance have not been established, but studies using global and 
tissue-specific knockout mice indicate the importance of the peripheral tissues liver, white adipose 
tissue (WAT) and muscle [2]. 
 
Previous studies in our lab identified distinct phases in development of glucose intolerance and 
inflammation in mice consuming a high-fat diet (HFD) in liver, WAT and muscle [4]. The mammalian 
sirtuins are proposed to be conserved nutritional sensors that operate in a concerted fashion to 
regulate glucose and lipid homeostasis and inflammatory responses [5-7]. While research has 
focused on SIRT1, all seven mammalian sirtuins (SIRT1 – 7) are likely to be involved in a molecular 
network orchestrating the response to glucose and lipids in a range of tissues [6). Sirtuin regulation 
of glucose and lipid induced inflammation may be a mechanistic link in the impact of HFD on 
metabolic health [5]. Studies in our lab have identified postprandial induction of SIRT1 gene 
transcription in parallel with inflammatory responses, with SIRT1 gene transcription levels negatively 
associated with TNFα [8]. Sirtuin activity is dependent on the co-factor nicotinamide adenine 
dinucleotide (NAD). NAD biosynthesis is controlled by a number of enzymes, the dietary intake of 
tryptophan, niacin and nicotinamide riboside precursors, together with salvage pathways that direct 
biosynthesis from intermediate molecules [9].  
 
Sirtuins are activated in response to metabolic stressors such HFD, while NAD biosynthesis is 
compromised at the same time [5,10,11]. This implies the potential for the system to become 
overwhelmed in response to chronic challenges. This may contribute to the development of 
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metabolic dysfunction. This is supported by studies showing that the sirtuin/NAD system is 
compromised by HFD, diet-induced obesity and metabolic stress [5,12,13]. Conversely, activation of 
the sirtuin/NAD system has been shown to improve fasting serum insulin and glucose and insulin 
sensitivity [3,14].  
 
The liver, white adipose tissue (WAT) and muscle are all involved in glucose and lipid homeostasis 
and sirtuin regulated processes are known to be important in these tissues [2,15]. Studies in our lab 
indicated that while HFD can induce marked glucose intolerance within days, increased 
inflammatory markers in liver, adipose and muscle are initially transitory [4]. However, a second 
phase of increased glucose intolerance with long-term HFD is associated with marked increased 
adiposity and increased inflammation [4]. The potential role of the sirtuin/NAD system in the liver, 
WAT and muscle tissue in response to HFD in this process is not clear. Thus, the interplay between 
the seven members of the sirtuin gene family and the genes encoding enzymes that regulate the 
biosynthetic pathways to generate NAD is investigated in this study with a focus on transcriptional 
regulation to exploit the potential of this system in developing strategies to restore and maintain 
metabolic health.  
 
2. Materials and Methods 
2.1 Animals  
The present study was conducted using tissue from mice used in our previous study [4]. Animal 
studies were licensed under the Animal (Scientific Procedures) Act of 1986 with approval from the 
Rowett Institute of Nutrition and Health’s Ethical Review Committee. Briefly, male C57BL/6 mice 
(n=12 per diet group), 12 weeks of age were fed a HFD (60% of energy from fat) or a LFD diet (10% of 
energy from fat) (D12492 and D12450B, respectively, Research Diets, NJ, US) ad libitum. Sirtuin/NAD 
system components associated with our previous observations of distinct phases of the 
development of diet induced obesity and glucose intolerance [4] were examined in mice fed diets for 
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3 or 7 days (acute response) or 1, 4, 8, 12 or 16 weeks (chronic response). Food intakes, body 
weights, MRI scans (EchoMRI, Houston, TX, USA) and tissue collection (n=8-12) were as reported 
previously [4]. The mice were housed in a 12 h light/12 h dark cycle. All mice were sacrificed within a 
3 hour period beginning at 2.5 hours from the start of the 12 hour light cycle. 
 
2.2 mSIRTNADplex assay  
Total RNA (liver, WAT, soleus muscle) extraction was described previously [4]. Total RNA (50 ng) was 
assayed (n=6–8) for sirtuin and NAD biosynthetic enzyme gene expression using our in-house custom 
designed assay, the mSIRTNADplex. The procedures for design and optimisation of the 
mSIRTNADplex and the selected gene targets and primer assays are detailed in Supplementary files 
S1 and S2 respectively.  
 
2.3 NAD/NADH assay  
NAD and NADH levels were measured using a commercially available fluorimetric assay kit (Abcam, 
Cambridge, UK) and a Spectra Max Gemini XS fluorimeter (Molecular Diagnostics) (fluorescence 
excitation 540nm/emission 590nm). NAD and NADH were extracted from tissue lysates (n=5–8) 
using the solutions suppled with the kit. NAD and NADH were specifically recognised and detected 
using an enzyme cycling reaction. Background fluorescence was subtracted from tissue lysate NAD, 
NADH and total NAD/NADH was then assessed using the standard curves generated with the NAD 
and NADH standard stock solutions supplied with the kit.  
 
2.4 ELISA 
Protein homogenates were prepared by bead-grinding ~20mg tissue with PreCellys 24 (Bertin 
Technologies, UK) in 400ul of phosphate buffer (pH 7.4).  Homogenates were centrifuged at 5000 x g 
and aliquots of supernatants were frozen at -70 C until analysis. Protein concentration was 
estimated using Bradford Reagent (B6916 Sigma, UK) and serum bovine albumin standards with 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
7 
Funding: The Scottish Government's Rural and Environment Science and Analytical Services Division.  
 
absorbance measured at 595 nm. ELISA kits were used to assay SIRT4 (Wuhan EIAab Science Co.,Ltd., 
antibodies-online GmbH, Germany) and NMNAT3 (MyBioSource, San Diego, USA) in the prepared 
homogenates according to the manufacturer’s instructions using standards supplied with the ELISA 
kits and a Microquant KC4 (Biotek Instruments Inc.) to measure absorbance at 450nm. 
2.5 Plasma hormones and lipids  
Plasma hormones, cytokines (insulin, leptin, IL-1β, IL-6, TNFα) and lipids (HDL and LDL cholesterol, 
triacylglycerol and non-esterified fatty acids) were assessed in the same mice (n=6–8) and reported 
previously [4].   
 
2.6 Glucose tolerance  
Intra-peritoneal glucose tolerance tests (IPGTTs) were performed on a separate group of mice (n=6-
8), as reported previously [4].  
 
2.7 Statistical Analysis  
Principal Component Analysis (PCA) was performed using SIMCA-P+ 12.0 software (MKS Instruments 
UK Ltd, Cheshire) on normalised gene expression data. Two-way analysis of variance (ANOVA) was 
performed on normalised gene expression and protein data with diet and time as factors, using Gen 
Stat®13th Edition (VSN International, Ltd., Hemel Hempstead, UK). A post-hoc Bonferroni or Tukey’s 
correction for multiple comparisons of time points within an ANOVA was applied (significance level 
0.05) to gene expression and protein data respectively. ANOVA was conducted on a log scale if data 
was skewed. Pearson correlations were calculated using Genstat. Pairwise comparisons of tissue 
NAD and NADH levels were conducted using Student’s ttest (significance level 0.05). 
 
3. Results 
3.1 Acute and chronic responses to HFD 
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Phenotypic data for the mice were reported previously [4] and are summarised here in the Graphical 
Abstract accompanying this manuscript. Briefly, body weight and adiposity of HFD mice increased 
significantly after 3 days of HFD and increased linearly with time when compared to LFD mice [4]. 
The acute response within 3 days of HFD and glucose intolerance assessed by intraperitoneal glucose 
tolerance tests (IPGTT) (50% increase in area under the curve, AUC) was attributed to increased 
caloric intake and fat content of the diet respectively. Glucose intolerance then improved to 30% 
after 1 week, remaining steady up to 12 weeks. After 12 weeks a further increase in glucose 
intolerance (60% AUC) was observed concomitant with WAT and muscle inflammation (chronic 
response) characterised by increased expression of inflammatory gene markers (see summary 
Graphical Abstract). 
 
3.2 Transcriptional responses of SIRT/NAD system to HFD in liver, WAT and muscle  
The mSIRTNADplex gene expression profiles were assayed in liver, WAT and muscle from mice fed a 
HFD for 3 or 7 days (acute response) and for 1, 4, 8, 12 or 16 weeks (chronic response) to determine 
transcriptional responses of specific components of the sirtuin/NAD system involved in diet-induced 
obesity and the development of glucose intolerance.  Gene expression data analysed using GeNorm 
(http://medgen.ugent.be/genorm/) identified UBE2D2 as the most stable reference gene and all 
data was normalised to UBE2D2.  
 
PCA of mSIRTNADplex gene expression profiles revealed distinctly different sirtuin/NAD system gene 
expression profiles associated with each tissue (Supplementary file S3 Figure S1). This was 
characterised by high levels of QPRT and TDO2 in liver, HIC1 and PARP1 in WAT and muscle and 
NMRK2 in muscle. Tissue specific responses to HFD  and differing effects associated with the 
duration of HFD were apparent from cluster patterns of mSIRTNADplex data from HFD compared to 
LFD mice in all three tissues, liver (Figure 1A-B), WAT (Figure 1C-D) and muscle (Figure 1E). 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
9 
Funding: The Scottish Government's Rural and Environment Science and Analytical Services Division.  
 
This prompted further interrogation of significant changes in gene expression. ANOVA confirmed 
tissue specific and temporal regulation of the sirtuin/NAD system in C57Bl/6 mice in response to a 
HFD with diet and time a main effect for expression of several genes (Supplementary File S4 Figure 
S2). In liver this comprised 15 genes influenced by diet as a main effect. SIRT2 (p=0.017), PPIB 
(p<0.001), SIRT1 (p<0.001), SIRT7 (p=0.004), PARP1 (p=0.022), ABCA1 (p=0.047) and NMNAT1 
(p=0.011) were up-regulated in the acute phase (3 and 7 days) (Supplementary File S4 Figure S2A), 
but not during the chronic phase (1 - 16 weeks) (Supplementary File S4 Figure S2B).  Conversely, 
NMNAT3 (p<0.001) was up-regulated by HFD at 8 and 16 weeks (Supplementary File S4 Figure S2B). 
HIC1 (p<0.021), SIRT4 (p<0.001), NAPRT1 (p<0.001), NMNAT2 (p<0.033), NAMPT (p<0.018), TDO2 
(p<0.001) and NNMT (p<0.001) were up-regulated in HFD mice at all time points (Supplementary File 
S4 Figure S2). Notably, not all seven mammalian sirtuins transcripts are regulated in response to HFD 
(Supplementary File S4 Figure S2). Time was also a factor influencing gene expression, with SIRT1 
(p=0.002), NADSYN1 (p=0.017), QPRT (p=0.002), SIRT4 (p<0.001), TDO2 (p<0.001) and NNMT 
(p<0.001) transcripts down-regulated in the liver of both LFD and HFD mice during the latter stages 
of the experiment (Supplementary File S4 Figure S2B).  
 
In WAT HFD was indicated as a main effect for 7 gene targets. PNP, NMNAT2 and NMNT were up-
regulated. PNP (p=0.033) showed an early response to HFD at 3 and 7 days (Supplementary File S5 
Figure S3A), while NMNAT2 (p≤0.009) and NMNT (p≤0.004) were elevated in response to HFD 
throughout the period tested (Supplementary File S5 Figure S3). SIRT5, SIRT6, SIRT4 and NMNAT3 
were down-regulated in response to HFD (Supplementary File S5 Figure S3). SIRT5 (p=0.043) showed 
an early response to HFD at 3 and 7 days (Supplementary File S5 Figure S3A). While SIRT4 (p=0.012) 
and SIRT6 (p=0.009) were down-regulated in response to HFD within the period 1 to 16 and 1 to 12 
weeks respectively (Supplementary File S5 Figure S3B). NMNAT3 was down-regulated in response to 
HFD (Supplementary File S5 Figure S3) at 3 and 7 days (p=0.006) and within the period 1 to 16 weeks 
(p=0.17). Seventeen genes were changed in both LFD and HFD in response to time. SIRT2 (p<0.001), 
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PPIB (p<0.001), PSMB6 (p=0.021), SIRT1 (p=0.01), SIRT5 (p=0.034), NADSYN1 (p=0.003), PNP 
(p<0.001), NRMK1 (p=0.023), SIRT4 (p<0.001) and NMRK2 (p=0.002) were all down-regulated over 
time (Supplementary File S5 Figure S3B). SIRT3 (p=0.028) and SIRT7 (p=0.013) reached the lowest 
levels around week 12 (Supplementary File S5 Figure S3B). ABCA1 (p=0.001), NAMPT (p=0.037) and 
NMNAT3 (p=0.027) revealed variable expression with a tendency to reduce with time 
(Supplementary File S5 Figure S3B). 
 
In muscle HFD was indicated as a main effect for thirteen gene targets. Significant increases in HIC1 
(p=0.007), PSMB6 (p=0.009), SIRT5 (p<0.001), SIRT3 (p<0.001), NAPRT1 (p=0.022) NMRK1 (p=0.026), 
NMRK2 (p<0.001), CD38 (p<0.001), NMNAT1 (p<0.001) and NMNAT3 (p=0.002) were shown as a 
main effect of HFD (Supplementary File S6 Figure S4). Conversely, SIRT7 (p=0.003), ABCA1 (p<0.001) 
and NAMPT (p=0.007) decreased in response to HFD. Down-regulation of PPIB (p<0.001) and PSMB6 
(p<0.001) and up-regulation of SIRT1 (p=0.001) were observed in the mice as main effects of time 
(Supplementary File S6 Figure S4). 
 
More cautious statistical analysis (application of a post hoc Bonferroni correction) was applied to 
discriminate the most robust gene regulation responses to HFD in liver, WAT and muscle 
(summarised in Graphical Abstract). In liver significant increases in SIRT4 (p<0.001) and SIRT7 were 
apparent at 3 days of HFD (Figure 2A). SIRT4, PPIB and NAPRT1 were significantly up-regulated in 
response to HFD at 7 days (p<0.001) (Figure 2A). TDO2 and NNMT expression was higher in HFD 
mice at all but week 8 (p<0.001) (Figure 2B). In contrast NMNAT3 (p<0.001) only became 
significantly elevated following 8 weeks of HFD, remaining significantly elevated at 16 weeks (Figures 
2B). ABCA1 was the only transcript down-regulated with HFD, at 8(p<0.001) and 12 (p<0.004) weeks 
in muscle (Figure 2D) and liver respectively (Figure 2B). Robust up-regulation in response to HFD was 
also observed for NMNAT2 (p<0.003) in WAT at 7 days of HFD (Figure 2C) and NMRK2 (p<0.001) at 1 
week and CD38 (p<0.001) at 16 weeks in muscle (Figure 2D). In theory it would be expected that 
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significantly altered gene expression between LFD and HFD mice should be the same in the 7 day 
(acute phase experiment) and 1week (chronic phase experiment) groups. However, while this is not 
always the case it was noted that differences in gene expression are indeed similar, but fail to reach 
significance. This is readily explained by reduced statistical power for some genes and the use of 
Bonferroni adjusted p-values making the requirement for significance more stringent, unavoidably 
pushing up type II error rates. 
 
3.3 Correlated SIRT/NAD gene expression  
Several mSIRTNADplex genes exhibited correlated regulation with tissue type or HFD 
(Supplementary File S7 Table S2). SIRT4, SIRT7 and NAPRT1 gene expression is highly positively 
correlated in the liver (Figures 3A, 3B, 3C). In muscle NMRK2 and CD38 are significantly positively 
correlated (Figure 3D). Notably, co-regulated SIRT/NAD gene expression was often dependent on 
consumption of LFD or HFD.  Positively correlated gene expression of NMNAT3 with SIRT 4, SIRT7, 
NAPRT1 and NNMT in liver was lost when mice were fed HFD (Table 1). Conversely, TDO2 positively 
correlated gene expression with SIRT7, NAPRT1, SIRT 4 and ABCA1 in liver was only apparent when 
mice were fed HFD (Table 1). NMNAT3 and TDO2 were negatively correlated in liver only when mice 
were fed HFD (Table 1). ABCA1 also exhibited aberrant regulation with diet, being negatively 
correlated with NMNAT3 and positively correlated NAPRT1 only when fed HFD. Negatively 
correlated gene expression of ABCA1 and SIRT7 was only observed in liver of LFD mice (Table 1).  
 
3.4 Tissue specific SIRT/NAD gene regulation correlates with metabolic markers and HFD  
The genes exhibiting highly significantly altered expression in the liver, WAT and muscle in response 
to HFD demonstrate significant correlations with a number of metabolic markers (Supplementary 
File S8 Table S3). Correlation analysis demonstrates the reasons why PPIB, initially selected as a 
potential reference gene, proved unsuitable as a reference gene in this study. PPIB expression was 
negatively correlated with variables such as body weight (-0.43, p<0.001), fat mass (-0.45, p<0.001), 
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plasma HDL (-0.38, p=0.001), LDL (-0.35, p=0.003), leptin (-0.54, p=0.001) and insulin (-0.49, p=0.002) 
(Supplementary File S8 Table S3). Liver NMNAT3 transcripts were observed to be significantly 
correlated with body weight (0.61, p<0.001), plasma HDL (0.70, p<0.001) and leptin (0.77, p=0.008) 
(Supplementary File S8 Table S3). ABCA1 transcripts in liver exhibited a negative correlation with 
body weight (-0.37, p<0.001) and fat mass (-0.39, p<0.001) (Supplementary File S8 Table S3). 
NMNAT2 expression in WAT was significantly positively associated with body weight (0.30, p=0.004), 
fat mass (0.30, p=0.004), plasma LDL (0.25, p=0.037), HDL (0.34, p=0.004), leptin (0.37, p=0.028), 
insulin (0.40, p=0.017) and basal glucose (0.31, p=0.024) (Supplementary File S8 Table S3).  
 
However, other SIRT/NAD system genes demonstrate significant correlation with metabolic 
parameters dependent on dietary fat consumed, providing further evidence of deregulation of the 
SIRT/NAD system in response to HFD (Table 2). Deregulated transcriptional regulation in liver in 
response to HFD was demonstrated by the loss of significant positive correlated expression of SIRT7 
with LDL (LFD 0.53, p=0.001, HFD 0.29, p=0.077), NAPRT1 with body weight (0.44, p=0.002, HFD -
0.05, p=0.74), fat mass (0.49, p=0.001, HFD -0.05, p=0.749),  plasma HDL (0.35, p=0.04, HFD -0.08, 
p=0.65)  and leptin (0.67, p=0.001, HFD -0.24, p=0.345)  and NMNAT3 with plasma and glucose (0.51, 
p=0.007, HFD -0.02, p=0.907) (Table 2).  Conversely, several SIRT/NAD gene transcripts were 
significantly negatively associated with metabolic markers when mice were fed a HFD. These 
included liver SIRT7 with leptin (LFD 0.05, p=0.83, HFD -0.51, p=0.032), ABCA1 with plasma LDL (LFD 
0.01, p=0.966, HFD -0.34, p=0.042), HDL (LFD -0.02, p=0.259, HFD -0.62, p<0.001),  TG (LFD 0.11, 
p=0.529, HFD -0.42, p=0.01)  and insulin (LFD -0.27, p=0.286, HFD-0.51, p=0.031), TDO2 with plasma 
LDL (LFD -0.17, p=0.35, HFD -0.43, p=0.008), HDL (LFD 0.07, p=0.7, HFD -0.51, p=0.002),  TG (LFD 
0.05, p=0.78, HFD -0.54, p=0.001), leptin (LFD -0.40, p=0.35, HFD-0.65, p=0.003) and insulin (LFD -
0.08, p=0.763, HFD-0.55, p=0.018) and NNMT with HDL (LFD 0.13, p=0.466, HFD -0.58, p<0.001) 
(Table 2).   NMNAT2 in WAT was positively correlated with insulin when mice were fed a HFD (LFD -
0.06, p=0.802, HFD 0.51, p=0.038) (Table 2).  NMRK2 expression in muscle was significantly 
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negatively associated with body weight (LFD -0.05, p=0.812, HFD -0.53, p=0.003), fat mass (LFD 0.18, 
p=0.334, HFD 0.53, p=0.003), plasma HDL (LFD -0.28, p=0.226, HFD -0.54, p=0.01) and basal glucose 
(LFD -0.20, p=0.536, HFD -0.61, p=0.037) in HFD mice only (Table 2). ABCA1 expression in muscle was 
significantly negatively associated with body weight (LFD -0.42, p=0.021, HFD -0.01, p=0.964), fat 
mass (LFD -0.40, p=0.028, HFD -0.10, p=0.62) in LFD mice only (Table 2).  
 
3.5 Tissue NAD/NADH levels altered with HFD  
No significant changes in either total NAD+NADH, or NAD:NADH ratios were observed in 
comparisons of liver (n=5-8) from LFD or HFD mice at 3 days, 1 week or 16 weeks (data not shown). 
No significant changes in either total NAD+NADH were observed in comparisons of WAT from mice 
fed LFD or HFD at 3 days (Figure 4A), but HFD mice at 7 days had significantly increased total 
NAD+NADH (p=0.002) levels, a consequence of increased NAD (p=0.008) (Figure 4B). The NAD:NADH 
ratio was also significantly higher in WAT (n=5-8) from HFD mice at 3 (p=0.017) and 7 days (p=0.004) 
(Figure 4C). No significant changes in total NAD+NADH, or NAD:NADH ratios were observed in 
comparisons of muscle (n=3-6) from LFD or HFD mice at 1 week (Figure 4D). However, at 8 (p=0.069) 
(Figure 4E) and 16 weeks (p=0.0056) (Figure 4F) HFD mice had a reduction in total NAD+NADH. This 
indicated a reduction in NADH levels that was significant at 16 weeks (p=0.0096) (Figure 4F). An 
increased, but non-significant NAD:NADH ratio was also observed in muscle at 1 (p=0.08), 8 (p=0.16) 
and 16 (p=0.14)  weeks of HFD (Figure 4G). 
 
3.6 SIRT/NAD system transcriptional responses and development of glucose intolerance and 
inflammation  
IPGTT revealed two phases in development of glucose intolerance in C57Bl/6 mice consuming a HFD 
[4] (and summarised Graphical Abstract). The first phase occurred within 3 days and was associated 
with an acute phase response [4] (Graphical Abstract). This was followed by an improvement in 
glucose tolerance then a stable period with no significant difference between total AUC at the 
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individual time points of 1, 4, 8 and 12 weeks [4] (Graphical Abstract). The second phase was 
characterised by a 60% increase in AUC together with increased inflammation in the WAT and 
muscle [4] (Graphical Abstract). The acute phase response was characterised by elevated plasma 
levels of the inflammatory cytokine IL6 and the acute phase proteins, alpha1-antichymotrypsin 
(aACT), haptoglobin and serum amyloid A (SAA) and increased transcription of SERPIN3AN and SAA 
in liver during the acute phase response [4]. This study demonstrates altered regulation of specific 
sirtuin/NAD genes in the liver (Supplementary File S4 Figure 2A) in association with the acute 
response. The most robust changes (Figure 2A) are up-regulation of SIRT4 and SIRT7 and the enzyme 
NAPRT1 with NAD levels remaining stable. Conversely, NAD levels increase in WAT (Figure 4B) in 
association with NMNAT2 up-regulation (Figure 2C). 
 
The second phase of glucose intolerance developing between 12 and 16 weeks [4] (Graphical 
Abstract), is preceded by significant up-regulation of liver NMNAT3 at 8 weeks, which is maintained 
at 16 weeks and a down-regulation of ABCA1 at 12 weeks (Figures 2B). In WAT the chronic phase 
and associated inflammation (12 and 16 weeks) [4] does not appear to be associated with specific 
sirtuin/NAD system genes. Chronic phase elevations in muscle IL1β, IL6 and TNFα and lipid [4] is 
preceded by up-regulation of NRMK2 at 1 week, down-regulation of ABCA1 at 8 weeks and up-
regulation of CD38 by 16 weeks of HFD (Figures 2D) and is associated with decreased muscle NAD 
levels (Figure 4F). 
 
3.7 SIRT4 and NMNAT3 protein levels in liver 
Transcriptional regulation of the SIRT/NAD system to consumption of HFD appears to be more 
responsive in the liver compared to WAT or muscle. Consequently, the levels of two significantly 
altered transcripts, SIRT4 and NMNAT3 were assessed in liver. Similarly to gene transcription the 
levels of SIRT4 were reduced significantly over time in the acute experiment (p=0.039) (Figure 5A). 
Whereas a significant time.diet interaction (p=0.015) (Figure 5A) was observed in the chronic 
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experiment. This was largely attributed to an increased level of SIRT4 at 16 weeks in HFD mice 
(Figure 5A). In contrast to gene expression NMNAT3 protein levels were significantly decreased in 
response to HFD in the acute  experiment (p=012) (Figure 5B), while there was a trend to decreased 
NMNAT3 levels at 1 and 8 weeks with levels being equal by 16 weeks (Figure 5B).  
 
4. Discussion  
Studies have reported that the sirtuin/nicotinamide adenine dinucleotide (NAD) system is impaired 
in individuals with type 2 diabetes (T2D) and the associated risk factors, obesity, abnormal glucose 
and lipid metabolism [1-3]. The sirtuin/NAD system is complex and regulated at both transcriptional, 
post-translational and enzyme activity level. This study, focused on transcriptional regulation, set out 
to identify specific components of the sirtuin/NAD system involved in diet-induced obesity and the 
development of glucose intolerance using a previously validated mouse model that demonstrated 
two phases of development of glucose intolerance associated with diet induced obesity in liver, WAT 
and muscle [4]. Phased responses, with altered sirtuin/NAD gene transcription coincident with the 
acute and chronic responses to HFD were identified. In liver transcriptional responses of SIRT4, SIRT7 
and NAPRT1 are prominent during the acute response, indicating an important role in SIRT/NAD 
system responses to HFD induced stress in liver. However, there is a lack of concomitant increases in 
SIRT4 protein levels until 16 weeks of HFD consumption when mice become glucose intolerant. The 
transcriptional response may be induced in an attempt to maintain SIRT4 levels that appear to 
initially decrease with consumption of HFD. SIRT4 gene expression is no longer significantly elevated 
when SIRT4 protein levels are significantly elevated (Figure 5A). SIRT4 is a negative regulator of 
oxidative metabolism linked with suppression of enhanced SIRT1 and SIRT3 oxidative capacity 
[16,17] and is elevated in genetically diabetic mouse models [16]. Notably, changes in expression of 
SIRT4 and SIRT7 in response to HFD are positively correlated with NAPRT1 (Figure 3). NAPRT1, an 
important salvage pathway enzyme catalysing conversion of nicotinic acid to β-nicotinic acid 
mononucleotide (β-NAMN), can alleviate responses to oxidative stress in liver [18]. Loss of NAPRT1 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
16 
Funding: The Scottish Government's Rural and Environment Science and Analytical Services Division.  
 
regulation with prolonged consumption of HFD is potentially important in contributing to the 
resulting loss of metabolic homeostasis. Penke et al., [19] report increased liver NAD levels in mice 
consuming high fat diet concomitant with increased NAMPT gene and protein expression. Increased 
expression of enzymes synthesising NAD, NAMPT (salvage pathway synthesis from nicotinamide), 
(NAPRT1 (salvage pathway synthesis from nicotinic acid) and TDO2 (de novo synthesis from 
tryptophan) were apparent in this study, but were not associated with increased NAD levels in liver.  
It is probable in our study that elevation of NAMPT, NAPRT1 and TDO2 contribute to a compensatory 
response to increased demand for NAD in liver of HFD mice and maintenance of liver NAD:NADH 
ratios. The study by Penke et al., [19] supports this conclusion.   Supplementation with NAD 
precursors could provide added protection to the liver via this route [19]. Both TDO2 and QPRT, 
highly expressed in liver compared to WAT and muscle, reflect the capacity of the liver to convert 
tryptophan to NAD. The positive correlation of NAPRT1 and TDO2 is lost during the development of 
obesity, perhaps indicating that increased demand for NAD is limited with increased duration of 
HFD. Indeed the levels of TDO2 and QPRT tend to decrease from 1 – 16 weeks of HFD 
(Supplementary File S4 Figure S2). Thus it is likely that NAD/NADH ratios in liver will be adversely 
affected with continued HFD beyond the 16 week period tested in this study.  
 
The second phase of glucose intolerance in response to HFD, occurring after 12 weeks [4], is 
preceded by a second phase of liver sirtuin/NAD system gene regulation. The salvage pathway 
enzyme, NMNAT3, is significantly elevated after 8 weeks of HFD and remains so for the remainder of 
the study. NMNAT3 is proposed to be a mitochondrial salvage pathway enzyme [20] generating NAD 
from β-nicotinic acid mononucleotide (β-NAMN) and β-nicotinamide mononucleotide (β-NMN). This 
was disputed with failure to detect NMNAT3 in the mitochondrial proteome [21] and speculation 
surrounding NMNAT3 transcript variants [22]. Transcriptional elevation of NMNAT3 and TDO2 is not 
associated with increased levels of NAD in liver and is possibly a response to increased NAD demand 
and a loss of NMNAT3 protein. Increased NMNAT3 transcription may be a response to falling levels 
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of NMNAT3 in liver of HFD mice (Figure 5B). The second phase of glucose intolerance is also 
characterised by significantly down-regulated ABCA1 at 16 weeks of HFD. Hepatic ABCA1 is a rate-
limiting enzyme in HDL biogenesis [23] reported to improve B-cell function and glucose tolerance 
[24]. Notably, ABCA1 down-regulation in liver is preceded by down-regulation in muscle and 
elevated plasma HDL and LDL cholesterol and triglycerides. These events may mark the prelude to 
loss of metabolic homeostasis and development of glucose intolerance in the chronic phase. 
 
NNMT, elevated in HFD mice has been linked to development of obesity, diabetes and metabolic 
syndrome [25-27]. NNMT expression was not correlated with increasing fat mass in HFD mice, but is 
elevated when mice consume HFD. Research on NNMT has largely focused on its association with 
carcinogenesis [28,29]. Likewise SIRT7 has also been implicated in carcinogenesis [30, 31]. The up-
regulation of these transcripts in response to HFD may have implications for links between obesity 
and increased risk of hepatic cancer [32]. More recently NNMT has also been linked to metabolic 
benefits in liver with it’s product N1-methylnicotinamide reported to decrease serum and liver 
cholesterol [33]. However, although marked increases in NNMT expression was consistently 
observed in mice fed a HFD this did not prevent elevated serum cholesterol, but it is possible that 
up-regulation of the NNMT gene is an indication of liver responses to attempt to maintain 
homeostatic control of lipid homeostasis in response to consumption of a HFD. 
 
Transcriptional regulation of the sirtuin/NAD system was less pronounced in WAT compared to liver. 
This is not surprising as previous analysis indicated gains in adiposity and inflammation are not seen 
in WAT during the acute response in the liver in response to HFD [4]. However, prolonged HFD 
resulted in increases in adiposity and inflammation in WAT between 12 and 16 weeks. This is 
preceded by an elevation of NMNAT2 following 7 days on HFD, associated with increased levels of 
NAD and NAD:NADH ratios at 3 and 7 days of HFD. NMNAT enzymes generate NAD from the 
precursors, β-nicotinic acid mononucleotide (β-NAMN) and β-nicotinamide mononucleotide (β-
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NMN). This may indicate an adaptation to changes in WAT in response to increasing adiposity. There 
was a strong correlation of NMNAT2 with plasma insulin. Thus despite a lack of major changes in the 
sirtuin/NAD system in WAT, NMNAT2 transcripts appear to be associated with inflammation in WAT 
and glucose intolerance.  
 
Previous studies indicated that muscle tissue was not associated with the acute response to HFD [4]. 
The second phase of glucose intolerance in HFD mice revealed up-regulation of NMRK2 (1 week) and 
CD38 (16 weeks) and down-regulation of ABCA1 at 8 weeks. NMRK2 converts nicotinamide riboside 
to the NAD precursor, β-NMN [34].  NMRK2 expression is markedly higher in muscle compared to 
liver and WAT. NMRK2 increases NAD and insulin sensitivity [35]. High expression levels and robust 
responses to HFD provide evidence that NMRK2 is important in regulating NAD in muscle. Elevated 
NMRK2 is not maintained becoming negatively correlated with increased body weight and fat mass, 
plasma HDL and basal glucose (see Table 2). The onset of increased glucose intolerance between 12 
and 16 weeks is coincident with elevated CD38 (Figure 2D). CD38, a major NADase in tissues, is 
necessary for diet-induced obesity linked to sirtuins [36] and is supported by the significant positive 
correlations of muscle CD38 gene regulation with body weight and fat mass, plasma HDL and leptin 
(Table S3) and accumulation of lipid in muscle [4]. CD38 knockout mice fed a HFD have increased 
NAD levels, sirtuin activity and reduced fat droplets in muscle [36]. Notably, CD38 is regulated at the 
transcriptional level by IL6 [37] which is elevated in muscle of HFD mice at 12 and 16 weeks [4]. The 
reduced levels of NMRK2 with duration of HFD and the up-regulation of CD38 at 16 weeks, may 
contribute to the observed reduction in total NAD/NADH levels at this time. Analogous to the 
changes seen in WAT there was a trend towards increased NAD:NADH ratios in muscle in HFD mice. 
Christensen et al., [38] propose that increased NAD:NADH ratios are associated with altered energy 
metabolism and metabolic phenotype indicating reduced glycolysis and increased fatty acid 
biosynthesis. This may contribute to eventual loss of insulin sensitivity observed with long term high 
fat feeding. 
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The present study demonstrates a level of complexity in the regulation of the sirtuin/NAD system 
that has not previously been reported. This study identifies novel tissue specific transcriptional 
activation of key sirtuin/NAD system components in response to high fat diet, development of 
obesity and glucose intolerance and potential regulatory factors and transcriptional linkages 
involved. The regulation of rate-limiting enzymes of NAD biosynthesis appears to be important in the 
adaptive compensatory response in liver during the acute phase to prevent the negative impact of 
high fat diet and maintain glucose homeostasis and insulin sensitivity. Indeed, the novel finding of 
transcriptional activation of NAPRT1 supports previous reports of the importance of this enzyme in 
maintaining NAD levels in liver [40]. While activation of NMNAT3 implies a compensatory response 
specifically aimed at maintaining NMNAT3 protein and subsequently NAD pools in mitochondria.  
Ultimately, prolonged high fat feeding overwhelms the capacity to maintain homeostatic control 
concomitant with loss of insulin sensitivity in WAT and muscle. Notably, the activation of NMRK2, an 
important transcriptionally regulated salvage pathway enzyme in skeletal muscle [39] is not 
sustained with prolonged high fat feeding. ABCA1 was identified as an important component 
marking prelude to loss of metabolic homeostasis and development of glucose intolerance.  In 
summary this study has shown that multiple sirtuins that act as control points linked to NAD 
biosynthetic enzymes regulate metabolic signals, implicating several new sirtuin/NAD molecular 
targets for targeted intervention to protect against metabolic damage induced by diet-induced 
obesity.  
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Figures 
 
Graphical Abstract Summary of phenotypic data reported previously [4] and associated SIRT/NAD 
responses to HFD development of obesity and glucose intolerance.  
 
Figure 1 Principal component analysis (PCA) biplots of UBE2D2 normalised GeXP mSIRTNADplex data 
from (A, B) liver, (C,D) WAT and (E) muscle of mice fed either a low (Δ) or high (▲) fat diet. The 
number adjacent to each symbol represents the duration on the diet (A and C) at 3 and 7 days and 
(B, D and E) at 1, 4, 8, 12 and 16 weeks. The PCA biplot permits visualisation of inherent clustering 
patterns of individual tissue samples and associated gene expression levels (denoted by ● and gene 
symbol). The measurements all fall within the Hotelling T2 95% confidence limit. 
 
Figure 2 mSIRTNADplex gene expression profiles of mice fed either low (LF) or high (HF) fat diets. 
Mean expression for each gene (n=6-8 + SE) are shown for liver (A) 3 and 7 days and (B) 1, 4, 8 12 
and 16 weeks, WAT (C) 3 and 7 days and muscle (D) 1, 4, 8 12 and 16 weeks as indicated in the 
legend associated with each chart. Gene expression was assessed by mSIRTNADplex assay and 
normalised to internal reference gene UBE2D2. Significant (p < 0.05) differences in gene expression 
between LF and HF fed mice at time point tested assessed by ANOVA with Bonferroni correction are 
indicated (*). Significant gene changes are also summarised in Graphical Abstract. See 
Supplementary File S2 Table S1 for details of the genes in mSIRTNADplex and Supplementary Files 4, 
5 and 6 for mean expression profiles of all genes in the mSIRTNADplex for liver, WAT and muscle 
respectively. 
 
Figure 3 Correlation of SIRT/NAD system genes and metabolic markers. The experimental mice from 
both acute (Δ or ▲) and chronic (○ or ●) response experiments are shown. Responses to low (Δ or ○) 
and high (▲or ●) fat diet at 3 and 7 days (Δ or ▲) and 1, 4, 8, 12 and 16 weeks (○ or ●) are 
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indicated. (A-C) Correlations between liver SIRT4, SIRT7 and NAPRT1 expression (relative to UBE2D2) 
(n=92). (A) SIRT4 and SIRT7, (B) NAPRT1 and SIRT4, (C) NAPRT1 and SIRT7. Correlation coefficients of 
SIRT4 and SIRT7 were ρ=0.48, p<0.001 for all, ρ=0.48, p=0.001 for LF and ρ=-0.53, p<0.001 for HF 
mice, SIRT4 and NAPRT1 were ρ=0.66, p<0.001 for all, ρ=0.52, p<0.001 for LF and ρ=-0.53, p<0.001 
for HF, and NAPRT1 and SIRT7 were ρ=0.39, p<0.001 for all, ρ=0.41, p=0.005 for LF and ρ=-0.34, 
p=0.022 for HF. (D) Correlations between muscle CD38 and NMRK2 expression (relative to UBE2D2) 
in experimental mice (n=60). Correlation coefficients of CD38 and NMRK2 were ρ=0.37, p=0.003 for 
all, ρ=0.11, p=0.55 for LF and ρ=-0.15, p=0.45 for HF mice. (E-F) Correlations between liver TDO2 
(relative to UBE2D2) and body weight and fat mass (n=92). (E) TDO2 and body weight (g), (F) TDO2 
and fat mass (g). Correlation coefficients of TDO2 with body weight were ρ=-0.10, p=0.33 for all, ρ=-
0.40, p=0.007 for LF and ρ=-0.57, p<0.001 for HF mice and with fat mass were ρ=-0.11, p=0.302 for 
all, ρ=-0.39, p=0.007 for LF and ρ=-0.60, p<0.001 for HF mice. (G) Correlations between liver NNMT 
expression (relative to UBE2D2) and plasma HDL (n=70). Correlation coefficients were ρ=0.17, 
p=0.16 for all, ρ=0.14, p=0.47 for LF and ρ=-0.58, p<0.001 for HF mice respectively. 
 
Figure 4 NAD and NADH assay of WAT and muscle. Total NAD, NADH in response to LFD (□) or HFD 
(■) in WAT during acute phase (A) 3 and (B) 7 days and in muscle during chronic phase (D) 1 (E) 8 and 
(F) 16 weeks. The corresponding NAD/NADH ratios in (C) WAT and (G) muscle are shown. Pairwise 
comparisons of tissue NAD and NADH levels were conducted using Student’s ttest (significance level 
0.05). 
 
Figure 5 Expression levels of SIRT4 and NMNAT3 in liver of mice fed either low (LF) or high (HF) fat 
diets. Mean expression of proteins (n=6 + SE) are shown for SIRT4 (A) and NMNAT3 (B) the acute 
phase (3 and 7 days) and chronic phase (1, 8 and 16 weeks) experiments. Significant (p < 0.05) 
differences in protein expression between LF and HF fed mice at time point tested assessed by 
ANOVA with Tukey’s correction are indicated (*).  
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Tables 
 
Table 1 Sirtuin/NAD system gene expression in liver correlated with dietary fat. 
 
Table 2 Sirtuin/NAD system genes in liver, WAT and muscle that significantly correlate with dietary 
fat.  
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Table 1 
Sirtuin/NAD system gene expression in liver correlated with dietary fat 
 
Diet 
Group SIRT7 NAPRT1 SIRT4 ABCA1 NNMT 
 
TDO2 
NMNAT3 ALL 0.21 0.25 0.44 -0.40 0.34 -0.03 
 
LF 0.32 0.48 0.70 -0.07 0.40 -0.03 
 
HF 0.07 -0.21 -0.05 -0.68 -0.10 -0.58 
TDO2 ALL 0.27 0.56 0.64 0.51 - - 
 
LF 0.06 0.12 0.11 0.31 - - 
 
HF 0.32 0.53 0.58 0.73 - - 
ABCA1 ALL 0.16 0.25 - - - - 
 LF 0.33 0.03 - - - - 
 HF 0.04 0.41 - - - - 
        
ALL = all experimental mice, LF = low and HF = high fat fed mice. Bold font and underline  
indicates p < 0.05. Negative correlation indicated by negative value. 
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Table 2 Sirtuin/NAD system genes in liver, WAT and muscle that significantly  
correlate with dietary fat.  
                 DIET GROUP 
   ALL LFD HFD 
 TISSUE GENE    
 
Body weight Liver 
Muscle 
NAPRT1 
NMRK2 
ABCA1 
 0.26 
 0.06 
-0.33 
 0.44 
-0.05 
-0.42 
-0.05 
-0.53 
-0.01 
 
Fat mass Liver 
 
Muscle 
NAPRT1 
NMNAT3 
NMRK2 
ABCA1 
 0.26 
 0.65 
 0.14 
-0.38 
 0.49 
 0.28 
 0.18 
-0.53 
-0.05 
 0.65 
-0.53 
-0.10 
 
Plasma LDL Liver 
 
SIRT7 
ABCA1 
TDO2 
 0.40 
-0.20 
-0.20 
 0.53 
-0.01 
-0.17 
 0.29 
-0.34 
-0.43 
 
Plasma HDL Liver 
 
 
 
Muscle 
NAPRT1 
ABCA1 
TDO2 
NNMT 
NMRK2 
 0.34 
-0.37 
 0.11 
 0.17 
 0.15 
 0.35 
-0.20 
 0.07 
 0.17 
-0.28 
-0.08 
-0.62 
-0.51 
-0.58 
-0.54 
 
Plasma TG Liver 
 
ABCA1 
TDO2 
-0.19 
-0.38 
 0.11 
 0.05 
-0.42 
-0.54 
 
HDL/LDL ratio Liver 
 
NAPRT1 
ABCA1 
TDO2 
-0.17 
 0.26 
 0.24 
-0.46 
 0.09 
 0.18 
 0.20 
 0.43 
 0.58 
 
Plasma leptin Liver 
 
SIRT7 
NAPRT1 
TDO2 
-0.32 
 0.09 
-0.15 
 0.05 
 0.67 
-0.40 
-0.51 
-0.24 
-0.65 
 
Plasma insulin Liver 
 
 
WAT 
ABCA1 
NMNAT3 
TDO2 
NMNAT2 
-0.28 
 0.59 
-0.15 
 0.40 
-0.27 
-0.28 
-0.08 
-0.06 
-0.51 
 0.66 
-0.55 
 0.51 
 
Basal glucose Liver 
Muscle 
NMNAT3 
NMRK2 
 
 0.32 
 0.09 
 0.51 
 0.20 
-0.02 
-0.61 
      
ALL = all experimental mice, LF = low and HF = high fat fed mice. Bold font and underline  
indicates p < 0.05. Negative correlation indicated by negative value. 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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